Business Context and Reporting Period
This Form 8-K was filed by vTv Therapeutics Inc. on December 22, 2022. The company is incorporated in Delaware and its Class A common stock (trading symbol: VTVT) is listed on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance matter regarding the company's stock listing status.
Material Changes
The primary event reported is a notification from NASDAQ stating that the company is not in compliance with Rule 5550(a)(2). This non-compliance is due to the closing bid price of the Class A common stock remaining below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted 180 calendar days, until June 20, 2023, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price reaches or exceeds $1.00 per share for a minimum of 10 consecutive business days within the 180-day window.
- Current Status: The notification has no immediate effect on the listing of the stock.
- Risks: Management states there can be no assurance that the company will regain compliance. Failure to do so may result in the removal of the Class A common stock from the NASDAQ Capital Market, subject to an appeals process.
- Management Action: The company intends to actively monitor the closing bid price and is evaluating available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of VTVT stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of trading at or above $1.00 before the June 20, 2023 deadline.
- Review any subsequent filings regarding potential reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Assess the risk of delisting if the company fails to meet the compliance deadline.